IGF2BP3 and leukemia: In MLL-AF4 leukemia, the deletion of IGF2BP3 mediated by CRISPR/Cas9 sensitizes MLL-AF4 leukemia to the effects of menin-MLL inhibition on cell growth and leukemic initiating cells in vitro, which shows potent antileukemic effects (165).